Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Inoue:2020:10.1016/j.chest.2020.03.037,
author = {Inoue, Y and Kaner, RJ and Guiot, J and Maher, TM and Tomassetti, S and Moiseev, S and Kuwana, M and Brown, KK},
doi = {10.1016/j.chest.2020.03.037},
journal = {Chest},
pages = {646--659},
title = {Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype},
url = {http://dx.doi.org/10.1016/j.chest.2020.03.037},
volume = {158},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Biomarkers have the potential to become central to the clinical evaluation and monitoring of patients with chronic fibrosing interstitial lung diseases with a progressive phenotype. Here we summarize the current understanding of putative serum, bronchoalveolar lavage fluid and genetic biomarkers in this setting, according to their hypothesized pathobiologic mechanisms: evidence of epithelial cell dysfunction (eg, Krebs von den Lungen-6 antigen), fibroblast proliferation and extracellular matrix production/turnover (eg, matrix metalloproteinase-1), or immune dysregulation (eg, CC chemokine ligand 18). While most of the available data comes from idiopathic pulmonary fibrosis, the prototypic progressive fibrosing interstitial lung disease, there are data available in the broader patient population of chronic fibrosing interstitial lung diseases. While a number of these biomarkers show promise, none have been validated. In this review article, we assess both the status of proposed biomarkers for chronic fibrosing lung diseases with a progressive phenotype in predicting disease risk or predisposition, diagnosis, prognosis and treatment response, and provide a direct comparison between idiopathic pulmonary fibrosis and other chronic fibrotic interstitial lung diseases. We also reflect on the current clinical usefulness and future direction of research for biomarkers in the setting of chronic fibrosing interstitial lung diseases with a progressive phenotype.
AU  - Inoue,Y
AU  - Kaner,RJ
AU  - Guiot,J
AU  - Maher,TM
AU  - Tomassetti,S
AU  - Moiseev,S
AU  - Kuwana,M
AU  - Brown,KK
DO  - 10.1016/j.chest.2020.03.037
EP  - 659
PY  - 2020///
SN  - 0012-3692
SP  - 646
TI  - Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype
T2  - Chest
UR  - http://dx.doi.org/10.1016/j.chest.2020.03.037
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32268131
UR  - http://hdl.handle.net/10044/1/78979
VL  - 158
ER  -
Download